CRPC
Metastatic castration-resistant prostate cancer
Advertisement
The panel explores the distinct roles of alpha and beta emitters in radiopharmaceutical therapy for prostate cancer care.
The expert panel discusses emerging biomarkers and treatment combinations for CRPC and mHSPC.
The evolving role of RLT and radium-223 in managing metastatic mHSPC and CRPC is discussed.
The panel examines the impact of the latest data from ARANOTE and PEACE-3 in part three of this roundtable.
The panelists discuss key considerations for patient selection in doublet and triplet therapies for mHSPC and CRPC.
In part one of this roundtable, the panel discusses advances in imaging and tailored treatment strategies for prostate cancer
The phase 3 trial evaluates combination mevrometostat in patients with mCRPC previously treated with abiraterone acetate.
The real-world analysis of olaparib for HRRm+ CRPC showed that earlier treatment resulted in higher PFS and OS.
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
The panelists examine the existing data for T cell engagers in CRPC and how the data might affect clinical practice.
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
The primary endpoint of rPFS was maintained in both cohorts.
Dr. Dorff shares highlights from Uromigos Live 2024 and talks about the role of ADT in prostate cancer treatment.
Early phase I data on 177Lu rhPSMA-10.1 has demonstrated an encouraging safety profile for the novel radioligand therapy.
In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
In the fifth segment of our roundtable series, the treatment of patients with CRPC is discussed.
Dr. Oliver Sartor gives an overview of the SPLASH trial on PSMA-targeted therapies for patients with prostate cancer.
Experts at ESMO Congress 2024 discuss novel therapies for castration-resistant prostate cancer.
Experts review the CONTACT-02 trial as well as the Decipher score utilized in the STAMPEDE trial.
The roundtable of experts discuss the realities of the SPLASH trial's hazard ratio and overall survival results.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.